International Stem Cell CORP

International Stem Cell Corporation is a clinical stage biotechnology company focused on developing therapeutic and biomedical products. The company has two revenue-generating businesses: anti-aging and research products, which generated total revenue of $9.1 million for the year ended December 31, 2025, and $9.1 million for the year ended December 31, 2024. The company currently generates no revenue from its principal therapeutic and clinical product development operations. Its products are based on extensive experience with human cell culture and proprietary human parthenogenetic stem cells (hpSCs). These hpSCs are similar to human embryonic stem cells (hESCs) in their ability to differentiate into various cell types in the human body, but their derivation does not involve fertilized eggs or the destruction of human embryos. This technology also offers the potential for creating immune-matched cells and tissues to reduce transplant rejection. ISCO scientists have developed the first parthenogenetic, homozygous stem cell line, which could provide therapeutic cells for hundreds of millions of individuals with minimal immune rejection after transplantation. The company's manufacturing processes are designed to comply with current Good Manufacturing Practice (GMP) standards as defined by the U.S. Code of Federal Regulations and the Food and Drug Administration (FDA). The company is developing various cell types from its stem cells for potential therapeutic products, focusing on applications where cell and tissue therapy is established but functional cell or tissue supply is inadequate. The most promising clinical application of its technology is for neural stem cells (ISC-hpNSC®) to treat Parkinson's disease and potentially other central nervous system disorders like traumatic brain injury and stroke.